142 55. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5:769–84. 56. Hof J, Krentz S, van Schewick C, et al. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leuke- mia. J Clin Oncol. 2011;29:3185–93. 57. Lilljebjorn H, Rissler M, Lassen C, et al. Whole-exome sequencing of pediatric acute lymphoblastic leukemia. Leukemia; 2011. 58. Iacobucci I, Ferrarini A, Sazzini M, et al. Application of the whole transcriptome shotgun sequencing approach to the study of philadelphia-positive acute lymphoblastic leukemia. Blood Cancer Journal; 2012. 59. Carroll AJ, Crist WM, Link MP, et al. The t(1;14)(p34;q11) is nonrandom and restricted to T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood. 1990;76:1220–4. 60. Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lym- phoblastic leukemia. Cancer Cell. 2002;1:75–87. 61. van Oostveen J, Bijl J, Raaphorst F, et al. The role of homeobox genes in normal hematopoiesis and hematological malignancies. Leukemia. 1999;13:1675–90. 62. Soulier J, Clappier E, Cayuela JM, et al. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood. 2005;106:274–86. 63. Speleman F, Cauwelier B, Dastugue N, et al. A new recurrent inversion, inv(7)(p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemias. Leukemia. 2005;19:358–66. 64. Bernard OA, Busson-LeConiat M, Ballerini P, et al. A new recurrent and specific cryptic translocation, t(5;14)(q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia. Leukemia. 2001;15:1495–504. 65. Tycko B, Smith SD, Sklar J. Chromosomal translocations joining LCK and TCRB loci in human T cell leukemia. J Exp Med. 1991;174:867–73. 66. Clappier E, Cuccuini W, Cayuela JM, et al. Cyclin D2 dysregu- lation by chromosomal translocations to TCR loci in T-cell acute lymphoblastic leukemias. Leukemia. 2006;20:82–6. 67. Karrman K, Kjeldsen E, Lassen C, et al. The t(X;7)(q22;q34) in paediatric T-cell acute lymphoblastic leukaemia results in over- expression of the insulin receptor substrate 4 gene through ille- gitimate recombination with the T-cell receptor beta locus. Br J Haematol. 2009;144:546–51. 68. Rowe JM. Prognostic factors in adult acute lymphoblastic leu- kaemia. Br J Haematol. 2010;150:389–405. 69. Van Vlierberghe P, van Grotel M, Tchinda J, et al. The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood. 2008;111:4668–80. 70. Zipfel PA, Zhang W, Quiroz M, et al. Requirement for Abl kinases in T cell receptor signaling. Curr Biol. 2004;14:1222–31. 71. Hagemeijer A, Graux C. ABL1 rearrangements in T-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2010;49:299–308. 72. Flex E, Petrangeli V, Stella L, et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med. 2008;205:751–8. 73. Otsubo K, Kanegane H, Eguchi M, et al. ETV6-ARNT fusion in a patient with childhood T lymphoblastic leukemia. Cancer Genet Cytogenet. 2010;202:22–6. 74. Lahortiga I, De Keersmaecker K, Van Vlierberghe P, et al. Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet. 2007;39:593–5. 75. Hebert J, Cayuela JM, Berkeley J, et al. Candidate tumor- suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) Curr Hematol Malig Rep (2012) 7:133–143 display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood. 1994;84:4038–44. 76. Palomero T, Sulis ML, Cortina M, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med. 2007;13:1203–10. 77. Maser RS, Choudhury B, Campbell PJ, et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature. 2007;447:966–71. 78. O’Neil J, Grim J, Strack P, et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med. 2007;204:1813–24. 79. Ferrando A. NOTCH mutations as prognostic markers in T-ALL. Leukemia. 2010;24:2003–4. 80. Balgobind BV, Van Vlierberghe P, van den Ouweland AM, et al. Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. Blood. 2008;111:4322–8. 81. Van Vlierberghe P, Meijerink JP, Stam RW, et al. Activating FLT3 mutations in CD4+/CD8- pediatric T-cell acute lymphoblastic leukemias. Blood. 2005;106:4414–5. 82. Paietta E, Ferrando AA, Neuberg D, et al. Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leuke- mias. Blood. 2004;104:558–60. 83. Kleppe M, Lahortiga I, El Chaar T, et al. Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat Genet. 2010;42:530–5. 84. Remke M, Pfister S, Kox C, et al. High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15–16.1 as a genomic marker for unfavorable early treatment response. Blood. 2009;114:1053–62. 85. Van Vlierberghe P, Palomero T, Khiabanian H, et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet. 2010;42:338–42. 86. Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481:157–63. Zhang and colleagues performed whole genome sequencing of 12 ETP ALL cases identifying activating mutations in genes regulating cytokine receptor and RAS signaling (67 %), inactivating lesions disrupting hematopoietic development (58 %), and histone-modifying genes (48 %). Gene expression profile of ETP ALL resulted similar to that of normal and myeloid leukemia hematopoietic stem cells, suggesting the possibility that myeloid- directed therapies might improve the poor outcome of ETP ALL. 87. Sulong S, Moorman AV, Irving JA, et al. A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic sub- groups. Blood. 2009;113:100–7. 88. Mullighan CG, Williams RT, Downing JR, et al. Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL. Genes Dev. 2008;22:1411–5. 89. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306:269–71. 90. Breit S, Stanulla M, Flohr T, et al. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood. 2006;108:1151–7. 91. Asnafi V, Buzyn A, Le Noir S, et al. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood. 2009;113:3918–24.